• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新诊断的多发性骨髓瘤患者的血栓前凝血异常。

Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.

作者信息

Auwerda Johannes J A, Sonneveld Pieter, de Maat Monica P M, Leebeek Frank W G

出版信息

Haematologica. 2007 Feb;92(2):279-80. doi: 10.3324/haematol.10454.

DOI:10.3324/haematol.10454
PMID:17296591
Abstract

Prothrombotic coagulation abnormalities were analyzed in patients with untreated multiple myeloma. Increases in factor VIII, in von Willebrand factor (vWF) and a decrease in protein S were observed and these changes were strongly associated with disease stage. No difference in baseline coagulation parameters was found between patients with and without subsequent venous thromboembolism.

摘要

对未经治疗的多发性骨髓瘤患者的血栓前凝血异常进行了分析。观察到因子VIII、血管性血友病因子(vWF)增加以及蛋白S减少,且这些变化与疾病分期密切相关。有和没有随后发生静脉血栓栓塞的患者之间,基线凝血参数没有差异。

相似文献

1
Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.新诊断的多发性骨髓瘤患者的血栓前凝血异常。
Haematologica. 2007 Feb;92(2):279-80. doi: 10.3324/haematol.10454.
2
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.
J Thromb Haemost. 2003 Mar;1(3):445-9. doi: 10.1046/j.1538-7836.2003.00083.x.
3
Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.产生副蛋白的B细胞疾病患者的血栓前凝血异常。
Clin Lymphoma Myeloma. 2007 Jul;7(7):462-6. doi: 10.3816/clm.2007.n.027.
4
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
Leuk Res. 2008 Jul;32(7):1078-84. doi: 10.1016/j.leukres.2007.12.002. Epub 2008 Feb 1.
5
Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII.水通道蛋白2基因变异、静脉血栓形成风险以及血管性血友病因子和凝血因子VIII的血浆水平
Haematologica. 2008 Jun;93(6):959-60. doi: 10.3324/haematol.12296.
6
Temporary relief of symptomatic Von Willebrand disease by multiple myeloma.多发性骨髓瘤对症状性血管性血友病的临时缓解作用
J Thromb Haemost. 2005 May;3(5):1088-9. doi: 10.1111/j.1538-7836.2005.01269.x.
7
[Venous thromboembolic disease: which coagulation screening, for whom, when?].[静脉血栓栓塞性疾病:针对何人、何时进行何种凝血筛查?]
Rev Med Brux. 2005 Sep;26(4):S315-9.
8
Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.多发性骨髓瘤患者凝血酶生成的基线及治疗相关变化
Leuk Lymphoma. 2017 Apr;58(4):941-949. doi: 10.1080/10428194.2016.1219900. Epub 2016 Dec 8.
9
Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.使用微芯片流动腔系统监测3型血管性血友病患者的凝血因子治疗。
Thromb Haemost. 2017 Jan 5;117(1):75-85. doi: 10.1160/TH16-06-0430. Epub 2016 Oct 20.
10
Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers.静脉注射大剂量甲泼尼龙对凝血和纤溶标志物的影响。
Thromb Haemost. 2005 Aug;94(2):467-8.

引用本文的文献

1
Evaluation of risk factors for thromboembolic events in multiple myeloma patients using multiple machine learning models.使用多种机器学习模型评估多发性骨髓瘤患者血栓栓塞事件的危险因素。
Medicine (Baltimore). 2025 Feb 14;104(7):e41428. doi: 10.1097/MD.0000000000041428.
2
D-dimer predicts venous thromboembolism in multiple myeloma: a nested case-control study.D-二聚体预测多发性骨髓瘤患者的静脉血栓栓塞:一项巢式病例对照研究。
Res Pract Thromb Haemost. 2023 Oct 19;7(8):102235. doi: 10.1016/j.rpth.2023.102235. eCollection 2023 Nov.
3
Thrombotic Risk and Calculated Whole Blood Viscosity in a Cohort of Patients With New Diagnosis of Multiple Myeloma.
新诊断多发性骨髓瘤患者队列的血栓风险和计算全血黏度。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296231222477. doi: 10.1177/10760296231222477.
4
Factor VIII Activity in Relation to the Type of Thrombosis and Patient's Risk Factors for Thrombosis, Age, and Comorbidity.与血栓形成类型、患者血栓形成风险因素、年龄及合并症相关的凝血因子VIII活性
Eurasian J Med. 2023 Feb;55(1):9-13. doi: 10.5152/eurasianjmed.2023.22072.
5
Monoclonal Gammopathy of Thrombotic Significance.具有血栓形成意义的单克隆丙种球蛋白病
Cancers (Basel). 2023 Jan 12;15(2):480. doi: 10.3390/cancers15020480.
6
Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma.ST-Genesia 分析仪检测到新诊断多发性骨髓瘤患者的增强型凝血酶生成。
J Thromb Thrombolysis. 2023 Apr;55(3):464-473. doi: 10.1007/s11239-022-02765-8. Epub 2023 Jan 11.
7
Patients With Multiple Myeloma Have a Disbalanced Whole Blood Thrombin Generation Profile.多发性骨髓瘤患者的全血凝血酶生成谱失衡。
Front Cardiovasc Med. 2022 Jun 27;9:919495. doi: 10.3389/fcvm.2022.919495. eCollection 2022.
8
The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.血管性血友病因子/因子 VIII 在多发性骨髓瘤和其他血液系统恶性肿瘤中的血栓形成和癌症进展中的作用。
J Thromb Haemost. 2022 Aug;20(8):1766-1777. doi: 10.1111/jth.15773. Epub 2022 Jun 23.
9
Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release.不同治疗方案的多发性骨髓瘤患者静脉血栓栓塞的发生率:促凝微粒和细胞因子释放的作用
J Clin Med. 2022 May 11;11(10):2720. doi: 10.3390/jcm11102720.
10
Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma.多发性骨髓瘤中对当前抗血栓形成策略耐药的潜在机制。
Cancer Drug Resist. 2022 Mar 7;5(1):214-228. doi: 10.20517/cdr.2021.115. eCollection 2022.